A federal appeals court ruled Tuesday that the U.S. Food and Drug Administration (FDA) exceeded its legal authority by requiring 11 graphic warning labels on cigarette packaging and advertisements. A three-judge panel of the 5th U.S. Circuit Court of Appeals upheld a lower-court order that prevented the mandate from taking effect, siding with tobacco companies including R.J. Reynolds.
The decision is part of a long-standing legal dispute involving the Family Smoking Prevention and Tobacco Control Act of 2009. This law authorized the FDA to regulate tobacco products and mandated new warning labels. The agency's first attempt to implement graphic warnings in 2011 was blocked by a different appeals court on First Amendment grounds, leading to years of delays and subsequent litigation from health groups to compel agency action.
The FDA's most recent rule, issued in 2019, required 11 images illustrating health risks such as type 2 diabetes, cataracts, and various cancers. However, Circuit Judge Don Willett wrote that because Congress specifically listed nine warnings in the 2009 Act, the FDA could not legally add more. The court stated that "precision in legislation leaves no room for improvisation in execution."
The scale of the impact involves the entire U.S. tobacco market and all adult smokers who purchase these products. While the exact number of packages affected was not reported, the rule would have applied to every cigarette pack sold and every advertisement displayed nationwide. By blocking the 11-label requirement, the court has prevented a change that would have altered the visual appearance of every tobacco product retail environment in the country. The financial cost to companies for redesigning packaging and the potential impact on consumer behavior remain central to the ongoing dispute between the industry and health regulators.
The knock-on effect of this ruling limits the executive branch's ability to expand upon specific mandates set by Congress. It establishes a precedent within the 5th Circuit that the FDA must stick strictly to the nine warnings listed in the 2009 law. What happens next depends on whether the government seeks a review from the full appeals court or the U.S. Supreme Court. For now, the lower-court order from 2025 remains in place, and the FDA has not yet responded to the ruling.